Maggie L. Shaw

AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.

Recent ENDURANCE data support 2-year lenalidomide maintenance in standard-risk multiple myeloma and individualize when to stop.

Bhavana Bhatnagar, DO, says payer support for social needs, registries, and survivorship care can help patients access therapy and thrive.

Sagar Lonial, MD, lead investigator of the phase 3 EXCALIBER trial, dissects iberdomide data he presented at IMS 2026 and where mezigdomide fits in.

Fathi, of Mass General Brigham Cancer Institute, says PARADIGM trial data support azacitidine-venetoclax for induction-eligible patients.

Moffitt’s Andrew Kuykenda, MD, lead VERIFY trial investigator, says rusfertide offers durable response and manageable safety.

Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.

Duration of benefit "has to be part of the discussion," emphasizes Rogers of The James/The Ohio State Comprehensive Cancer Center.

The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."

Transplant is no longer the default for young, fit patients with a good donor if they achieve MRD-negative status, says Emily K. Curran, MD

Policy mandates and low-burden trial designs are key to equitable stem cell transplant access, explains Karilyn Larkin, MD.

Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.

Novel combinations may improve survival in Richter transformation, a hard-to-treat condition, says Adam Kittai, MD, of Perlmutter Cancer Center.

The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.

The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.

In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.

The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.

Madhav R. Seshadri, MD, speaks on CLL's shift toward fixed-duration, MRD-guided regimens, MRD testing barriers, and open questions on drug sequencing.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

Robust survivorship programs exist at some institutions, but needs vary widely from patient to patient, explains Bhavana Bhatnagar, DO.

For Bhavana Bhatnagar, DO, delivering bispecifics and CAR T-cell therapy requires infrastructure, education, SOPs, and experienced academic colleagues.

Within polycythemia vera, patients can be iron deficient while continuing to produce too many red blood cells, explains Andrew Kuykendall, MD.

However, the risk of these rare cancers is not enough to dissuade prescribing CAR T-cell therapy for CLL, explains Kerry Rogers, MD, The James.

The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.

Swarup Kumar, MD, emphasizes that preparation is central to positive outcomes and includes patient education and early intervention when needed.

Reference countries have limited room to simply raise their own drug budgets to absorb the pressure, the lead study author explains.

Policy changes could have the greatest impact on transplant equity, explains hematologic oncologist Karilyn Larkin, MD.

This new study from the VHA also shows neither cytoreductive therapy nor phlebotomy clearly lowers thrombosis risk.